Literature DB >> 25656292

Human leukocyte antigen-G polymorphism influences the age of onset and autoantibody status in rheumatoid arthritis.

C M Mariaselvam1, A B Chaaben, S Salah, D Charron, R Krishnamoorthy, R Tamouza, V S Negi.   

Abstract

The study was conducted to investigate the frequency of three gene polymorphisms in the 3'-untranslated region (3'-UTR) of human leucocyte antigen-G (HLA-G) gene in south Indian patients with rheumatoid arthritis (RA) and analyze their influence on disease susceptibility, phenotype and treatment response. HLA-G 14 bp insertion (Ins)/deletion (del) (rs66554220), HLA-G +3142G>C (rs1063320) and +3187A>G (rs9380142) polymorphism was analyzed in 221 RA patients and 200 healthy controls. Frequency of HLA-G genotypes or alleles did not differ between patients and controls. Analysis based on rheumatoid factor (RF) status revealed that the frequency of allele 'A' (rs9380142) was significantly higher in RF-positive than in RF-negative patients [84% vs 74%, Yates-corrected P value (Pc) = 0.04, odds ratio (OR) = 1.8, 95% confidence interval (CI) = 1.0-3.2]. A similar difference was maintained in RF-positive female patients than their RF-negative counterparts (83% vs 71%, Pc = 0.02, OR = 1.9, 95% CI = 1.0 to 3.4) and between RF-positive and RF-negative young onset RA (YORA) patients (84% vs 73%, Pc = 0.03, OR = 1.9, 95% CI = 1.0-3.2), suggesting that rs9380142 polymorphism influenced RF status. The 14 bp Ins allele of rs66554220 was significantly more prevalent in RF-positive YORA than in RF-positive late onset RA (LORA) patients (51% vs 25%, P = 0.03, OR = 3.1, 95% CI = 1.1-9.8). Frequency of the four major haplotypes [InsGA (48%), DelGA (22%), DelCG (18%), DelCA (9.7%)] observed did not differ between cases and controls. HLA-G does not appear to be a risk factor for development of RA in south Indian Tamils but may act as a genetic modifier of clinical phenotype in terms of autoantibody production, gender preference and age at disease onset.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HLA G polymorphism; late onset rheumatoid arthritis; rheumatoid arthritis; rheumatoid factor; young onset rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25656292     DOI: 10.1111/tan.12521

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  5 in total

1.  "HLA-G 3'UTR gene polymorphisms and rheumatic heart disease: a familial study among South Indian population".

Authors:  Maheshkumar Poomarimuthu; Sivakumar Elango; Sambath Soundrapandian; Jayalakshmi Mariakuttikan
Journal:  Pediatr Rheumatol Online J       Date:  2017-02-01       Impact factor: 3.054

2.  HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Authors:  Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

3.  Evaluation of HLA-G 14 bp Ins/Del and +3142G>C Polymorphism with Susceptibility and Early Disease Activity in Rheumatoid Arthritis.

Authors:  Mohammad Hashemi; Mahnaz Sandoughi; Seyed Amirhossein Fazeli; Gholamreza Bahari; Maryam Rezaei; Zahra Zakeri
Journal:  Adv Med       Date:  2016-08-16

Review 4.  Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases.

Authors:  Fabio Morandi; Roberta Rizzo; Enrico Fainardi; Nathalie Rouas-Freiss; Vito Pistoia
Journal:  J Immunol Res       Date:  2016-08-29       Impact factor: 4.818

Review 5.  The HLA-G Immune Checkpoint Plays a Pivotal Role in the Regulation of Immune Response in Autoimmune Diseases.

Authors:  Monika Zaborek-Łyczba; Jakub Łyczba; Paulina Mertowska; Sebastian Mertowski; Anna Hymos; Martyna Podgajna; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.